{
  "id": 13475912,
  "title": "Rapport Therapeutics CEO Abraham Ceesay sells $143,272 in stock",
  "url": "https://urgent.news/2026/10/10/rapport-therapeutics-ceo-abraham-ceesay-sells-143-272-in-stock",
  "topic": "finance",
  "section": "Finance & Markets",
  "published": "2026-10-10T17:31:06.000Z",
  "source": {
    "name": "Investing.com",
    "slug": "investing-com",
    "url": "https://www.investing.com/news/insider-trading-news/rapport-therapeutics-ceo-abraham-ceesay-sells-143272-in-stock-93CH-4942178"
  },
  "original_language": "en",
  "account": "Abraham Ceesay, CEO and director of Rapport Therapeutics (RAPP), sold $143,272 worth of company common stock in two transactions on October 6 and 7, 2026. The stock traded at $30.65, down 5% from the previous week and 42% below its 52-week high of $52.93. Analysts rate the stock slightly undervalued, with price targets ranging from $50 to $80. Ceesay disposed of 3,375 shares on October 6 at an average price of $32.0314 each. Two days later, he sold an additional 1,147 shares at an average of $30.66 per share. Both transactions were made following Rule 10b5-1 trading plans adopted by Ceesay in March 2026. Currently, he personally holds 452,245 shares through direct ownership and 81,729 shares indirectly via trusts.",
  "summary": null,
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 2,
    "also_reported_by": [
      {
        "outlet": "Investing.com",
        "title": "Appian CEO Matthew Calkins sells $1.69m in company stock",
        "url": "https://urgent.news/2026/10/10/appian-ceo-matthew-calkins-sells-1-69m-in-company-stock",
        "published": "2026-10-10T18:16:17.000Z"
      }
    ]
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}